If anyone remembers, BOT recieved substantial US institutional interest back in 2019 from fundie Cowen. Cowen took a massive placement and pushed BOT up into the high 20s in terms of SP, marking them at a market cap of 250M+ MC.
Roughly similar to what we would be trading at in the 20s right now. At the time BOT had two successful preclinical trials iirc, and a single Phase 1 human trial success. Then they tried a Phase 2 acne and we all know what happened.
IHL in my view will get even more interest thanks to Eddie Sugar and the US Instos and Banks that he will promote us to. By that time IHL will have completed our Phase 2B OSA Trial at the Alfred, our first in-human trial and a massive inflection point. If this is successful, along with other developments in our other clinical assets, it wouldn't be too far fetched IMO to list on the NYSE/NASDAQ at a 40-50c SP here, then watch it multiply from there once it's on the US markets.
Check out what happened as soon as GW Pharma IPO'd on the NASDAQ and listed a new ADS, which is likely what we are going to do.
Price fluctuations at this level will be laughable the same way we were once worried about in 0.001 pip differences only last year.
